{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:58:42Z","timestamp":1785455922098,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05320-6","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:25:09Z","timestamp":1780082709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High intratumoral CD8 positive T cell infiltration associated with pathologic complete response after neoadjuvant immunotherapy in locally advanced colon cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Hiroki","family":"Okabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Teraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Sumii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Toyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Omote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"5320_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566\u201376. https:\/\/doi.org\/10.1038\/s41591-020-0805-8.","journal-title":"Nat Med"},{"key":"5320_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2024;390:1949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med"},{"key":"5320_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2021.07.027","volume":"157","author":"I Gkekas","year":"2021","unstructured":"Gkekas I, Novotny J, Kaprio T, Beilmann-Lehtonen I, Fabian P, Edin S, et al. Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases. Eur J Cancer. 2021;157:1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.07.027.","journal-title":"Eur J Cancer"},{"key":"5320_CR4","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.22.01351","volume":"41","author":"K Ludford","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, et al. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High\/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023;41:2181\u201390. https:\/\/doi.org\/10.1200\/JCO.22.01351.","journal-title":"J Clin Oncol"},{"key":"5320_CR5","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","volume":"30","author":"PGM de Gooyer","year":"2024","unstructured":"de Gooyer PGM, Verschoor YL, van den Dungen LDW, Balduzzi S, Marsman HA, Geukes Foppen MH, et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med. 2024;30:3284\u201390. https:\/\/doi.org\/10.1038\/s41591-024-03250-w.","journal-title":"Nat Med"},{"key":"5320_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24:235\u201351. https:\/\/doi.org\/10.1097\/PAP.0000000000000162.","journal-title":"Adv Anat Pathol"},{"key":"5320_CR7","doi-asserted-by":"publisher","first-page":"9647","DOI":"10.3390\/curroncol30110699","volume":"30","author":"J Liu","year":"2023","unstructured":"Liu J, Li J, Luo F, Wu S, Li B, Liu K. The Predictive Value of CD3+\/CD8\u2009+\u2009Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer. Curr Oncol. 2023;30:9647\u201359. https:\/\/doi.org\/10.3390\/curroncol30110699.","journal-title":"Curr Oncol"},{"key":"5320_CR8","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)30789-X.","journal-title":"Lancet"},{"key":"5320_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"5320_CR10","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"key":"5320_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","volume":"9","author":"Z Yang","year":"2024","unstructured":"Yang Z, Gao J, Zheng J, Han J, Li A, Liu G, et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct Target Ther. 2024;9:56. https:\/\/doi.org\/10.1038\/s41392-024-01762-y.","journal-title":"Signal Transduct Target Ther"},{"key":"5320_CR12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.medj.2024.07.002","volume":"5","author":"Z Yang","year":"2024","unstructured":"Yang Z, Ma J, Han J, Li A, Liu G, Sun Y, et al. Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer. Med. 2024;5:1293\u2013e13064. https:\/\/doi.org\/10.1016\/j.medj.2024.07.002.","journal-title":"Med"},{"key":"5320_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336979","author":"Z Yang","year":"2026","unstructured":"Yang Z, Xia F, Li J, Jin J, Wang G, Lin G, et al. Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer. Gut. 2026. https:\/\/doi.org\/10.1136\/gutjnl-2025-336979. gutjnl-2025-336979.","journal-title":"Gut"},{"key":"5320_CR14","doi-asserted-by":"publisher","first-page":"103678","DOI":"10.1016\/j.esmoop.2024.103678","volume":"9","author":"M Duval","year":"2024","unstructured":"Duval M, Vanderbecq Q, Phou V, Cervantes B, Mas L, Bachet JB, et al. Performances of preoperative CT scan to predict the pTN stage for MSI\/dMMR localized colon cancers. ESMO Open. 2024;9:103678. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103678.","journal-title":"ESMO Open"},{"key":"5320_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1055\/s-0043-1767703","volume":"36","author":"B Xiao","year":"2023","unstructured":"Xiao B, Yu J, Ding PR. Nonoperative Management of dMMR\/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review. Clin Colon Rectal Surg. 2023;36:378\u201384. https:\/\/doi.org\/10.1055\/s-0043-1767703.","journal-title":"Clin Colon Rectal Surg"},{"key":"5320_CR16","doi-asserted-by":"publisher","first-page":"113356","DOI":"10.1016\/j.ejca.2023.113356","volume":"194","author":"DA Fox","year":"2023","unstructured":"Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, et al. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023;194:113356. https:\/\/doi.org\/10.1016\/j.ejca.2023.113356.","journal-title":"Eur J Cancer"},{"key":"5320_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun S, Liu L, Zhang J, Sun L, Shu W, Yang Z, et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. J Hematol Oncol. 2025;18:84. https:\/\/doi.org\/10.1186\/s13045-025-01732-z.","journal-title":"J Hematol Oncol"},{"key":"5320_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1078-0432.CCR-23-2213","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Qin G, Bai F, Wu X, Ke H, et al. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer. Clin Cancer Res. 2024;30:368\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2213.","journal-title":"Clin Cancer Res"},{"key":"5320_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006611","author":"I G\u00f6genur","year":"2024","unstructured":"G\u00f6genur I, Justesen TF, Tarpgaard LS, Bulut M, Hansen TF, Jensen LH, et al. Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical Trial. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006611.","journal-title":"Ann Surg"},{"key":"5320_CR20","doi-asserted-by":"publisher","first-page":"0488","DOI":"10.34133\/research.0488","volume":"7","author":"S Sun","year":"2024","unstructured":"Sun S, Yang Z, Yao H, Zhang Z. Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1\/PD-L1 Immunotherapy. Res (Wash D C). 2024;7:0488. https:\/\/doi.org\/10.34133\/research.0488.","journal-title":"Res (Wash D C)"},{"key":"5320_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.trecan.2024.10.002","volume":"11","author":"S Sun","year":"2025","unstructured":"Sun S, Yang Z, Yao H, Zhang Z. A new enhancer for anti-PD-1\/PD-L1 immunotherapy: PCSK9 inhibition. Trends Cancer. 2025;11:84\u20137. https:\/\/doi.org\/10.1016\/j.trecan.2024.10.002.","journal-title":"Trends Cancer"},{"key":"5320_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ijc.34891","volume":"155","author":"C Meng","year":"2024","unstructured":"Meng C, Sun L, Shi J, Li Y, Gao J, Liu Y, et al. Exploring causal correlations between circulating levels of cytokines and colorectal cancer risk: A Mendelian randomization analysis. Int J Cancer. 2024;155:159\u201371. https:\/\/doi.org\/10.1002\/ijc.34891.","journal-title":"Int J Cancer"},{"key":"5320_CR23","doi-asserted-by":"publisher","first-page":"968089","DOI":"10.3389\/fimmu.2022.968089","volume":"13","author":"Y Mao","year":"2022","unstructured":"Mao Y, Xu Y, Chang J, Chang W, Lv Y, Zheng P, et al. The immune phenotypes and different immune escape mechanisms in colorectal cancer. Front Immunol. 2022;13:968089. https:\/\/doi.org\/10.3389\/fimmu.2022.968089.","journal-title":"Front Immunol"},{"key":"5320_CR24","doi-asserted-by":"publisher","first-page":"1602452","DOI":"10.3389\/fonc.2025.1602452","volume":"15","author":"W Hou","year":"2025","unstructured":"Hou W. Role of TGF\u03b2-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy. Front Oncol. 2025;15:1602452. https:\/\/doi.org\/10.3389\/fonc.2025.1602452.","journal-title":"Front Oncol"},{"key":"5320_CR25","doi-asserted-by":"publisher","first-page":"103698","DOI":"10.1016\/j.esmoop.2024.103698","volume":"9","author":"JR Platt","year":"2024","unstructured":"Platt JR, Allotey J, Alouani E, Glasbey J, Intini R, Lonardi S, et al. Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series. ESMO Open. 2024;9:103698. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103698.","journal-title":"ESMO Open"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05320-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05320-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05320-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:14:23Z","timestamp":1785453263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05320-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5320"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05320-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of NHO Fukuyama Medical Center and conducted in accordance with the Declaration of Helsinki. Due to the retrospective nature of the study, the requirement for informed consent was waived by the Institutional Review Board. Due to the retrospective nature of the study, the requirement for informed consent to participate was waived by the Institutional Review Board.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent to publish this case report and any accompanying images was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1097"}}